CA-ALKIRA/CHECK-POINT
29.9.2021 16:12:04 CEST | Business Wire | Press release
Cloud networking pioneer Alkira® and Check Point Software Technologies (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced a technology alliance to provide Check Point Software’s CloudGuard firewalls in Alkira’s Cloud Network infrastructure as-a-Service (CNaaS). This comes as organizations deploying application workloads to the cloud are struggling with the complexity of implementing consistent enterprise-wide security controls spanning cloud, multi-cloud and on-premises environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005357/en/
The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads enabling customers to deploy the same robust security in the cloud that they are used to with on-premises systems. Alkira brings a high-performance cloud network-as-a-service with global virtual infrastructure, advanced routing, intelligent service insertion and dynamic auto-scale, simplifying set-up and day 2 operations for enterprise cloud networking and security deployments.
Atif Khan, CTO and Founder of Alkira, said:
“Alkira and Check Point simplify security deployments and make it easier for enterprise customers to apply a single security posture across the entire enterprise network spanning cloud, multi-cloud and existing data center or colocation facilities. Delivering the Alkira virtual network infrastructure and Check Point security management tools as a service allows enterprises to avoid the costs and complexity of DIY solutions, and provides guaranteed performance and scalability.”
TJ Gonen, Head of Cloud Security at Check Point added
:
“The combination of Check Point CloudGuard and Alkira simplifies the process of provisioning and ongoing management in the cloud networking environment which is a big win for enterprise customers. The Check Point CloudGuard platform provides cloud native security with advanced threat prevention for all assets and workloads, across public, hybrid and multi-cloud environments, enabling customers to benefit from a single unified security platform.”
Alkira Cloud Services Exchange® (CSX) fully automates the provisioning, licensing, service insertion, scaling and health monitoring of CloudGuard network security gateways. Alkira seamlessly inserts the CloudGuard gateways at any point in the Alkira global cloud backbone, providing stateful security controls for any on-premises, cloud, and Internet application traffic. Alkira allows customers to decouple CloudGuard from the specific cloud providers, thus providing a more efficient multi-cloud security architecture.
Cloud environments offer global presence and vast compute resources but lack the necessary routing, policy and operational controls enterprises require for a streamlined cloud firewall deployment. Even in a single cloud environment, do-it-yourself solutions result in a complex sprawl of virtual machine instances and traffic management scenarios. They also tend to make inefficient use of resources. All these problems are made worse in multi-cloud environments.
Check Point CloudGuard can be rapidly provisioned into one or multiple globally distributed Alkira Cloud Exchange Points (CXP) to provide security policy enforcement for application traffic between any set of endpoints connected to the Alkira global cloud backbone. Once CloudGuard has been provisioned within an Alkira CXP it can provide:
- Security policy to and between public clouds
- Cloud hosted, stateful firewall services for branches and data centers
- Regionalized Internet breakouts for secure SaaS application access
- Cloud DMZ environment for Internet facing applications
- Shared cloud application services for partners and M&As
Alkira’s visual policy manager simplifies policy configuration, scoping and inspection, and streamlines auditing for assurance and compliance purposes. Alkira’s intent-based approach selectively routes traffic to firewalls according to need, improving efficiency of firewall utilization and optimizing network performance. Customers have a choice of bring-your-own license (BYOL) or pay-as-you-go (PAYG) licensing models.
Check Point offers a multilevel security architecture that defends enterprises’ cloud, network and mobile device-held information, and a comprehensive and intuitive one-point-of-control security management system.
CloudGuard is available in the Alkira network services marketplace.
For more information:
- Download the Alkira and Check Point solution brief .
- Join the Alkira and Checkpoint webinar October 13
About Alkira
Alkira® delivers Cloud Networking as-a-Service (CNaaS) and developed the first Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and security services, and end-to-end visibility and governance. Alkira Cloud Services Exchange® (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira CSX is available on the AWS and Azure Marketplaces. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP and founding team member at Viptela. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet
Alkira® , Alkira Cloud Services Exchange® and Alkira Cloud Exchange Point® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005357/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
